Verdict: Side-by-side breakdown using the Bull Rankings model. JAZZ scored 73.9, EXEL scored 79.6 — EXEL leads.
Compare another set
JAZZ
Jazz Pharmaceuticals plc
Biotechnology · Quality-Growth
73.9
$216.75 · $14.1B
fundamentals as of
Score gap
5.7
EXEL leads
EXEL
Exelixis, Inc.
Biotechnology · Quality-Growth
79.6
$59.82 · $14.8B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestJAZZ14.9x
Fastest growthJAZZ+12.6%
Strongest balance sheetEXEL0.09
Highest qualityEXEL97 / 100
Largest discount to fair valueJAZZ-51%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
JAZZ
stronger →← stronger
EXEL
58
Qualityreturns · margins · balance sheet
97
88
Growthrevenue & earnings expansion
77
79
Valuevaluation vs sector peers
67
JAZZ is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
JAZZ
EXEL
$1.6bC+
FCF
$1.2bC+
+12.6%B+
Rev
+9.2%B
0.92C
D/E
0.09B+
14.9xA-
P/E
18.9xA-
0.96B+
PEG
2.56C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
JAZZ
EXEL
51% below
Price vs fair valuelower is cheaper
38% below
~-9%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~0%/yr
+82%
1-yr DCF upside
+34%
+104%
5-yr DCF upside
+62%
+139%
10-yr DCF upside
+112%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
JAZZ
Why this score
Diluting shareholders
EXEL
Why this score
Buying back stock
Durable high returns
The companies
JAZZJazz Pharmaceuticals plc
Biotechnology · $216.75 · beta 0.37
Why now
Biotechnology · market cap $14.1b. 19% off the 52-week high of $266.38. Revenue growing +13%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 22 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $294.64 (implying +36% upside).
Moat
Net margin 20% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 169% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
EXELExelixis, Inc.
Biotechnology · $59.82 · beta 0.47
Why now
Biotechnology · market cap $14.8b. Trading near 52-week high of $61.66 — momentum setup, limited technical margin of safety. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $54.87 (implying -8% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where JAZZ and EXEL diverge
On the headline score the gap is 5.7 points in favor of EXEL. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityJAZZ 58.5 · EXEL 96.6EXEL +38.1
ValueJAZZ 78.7 · EXEL 67.4JAZZ +11.3
GrowthJAZZ 87.6 · EXEL 77.5JAZZ +10.1
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is EXEL or JAZZ the better stock?
EXEL scores higher: EXEL 79.6, JAZZ 73.9 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do EXEL and JAZZ differ most?
The widest gap is quality, where EXEL leads by 38 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are EXEL and JAZZ scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.